Search filters

List of works by Mario Mandala

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

scientific article published on 10 September 2017

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

scientific article published on 20 December 2018

BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome

scientific article published on 24 February 2017

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

scientific article published on 8 March 2017

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

scientific article published on 01 November 2020

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

scientific article

Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres

scientific article published in 2021

Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma.

scientific article published on 29 May 2013

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

scientific article published on 05 August 2019

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

scientific article published on 15 January 2018

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

article

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Melanoma brain metastases: review of histopathological features and immune-molecular aspects

scientific article published on 08 June 2020

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review

scientific article published in 2021

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

scientific article published in February 2016

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

scientific article

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

scientific article published on 12 September 2018

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

scientific article published on 27 March 2019

Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study

article

Reply to E. Hindié and K.R. Hess

scientific article published on 02 April 2019

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

scientific article

The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis

scientific article published on 09 July 2019

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

scientific article

Paulina is supported by:

About Paulina

Help